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Volume 50, Number 2 Letters to the Editor 475that in addition to the volume of intraluminal thrombus, its
location and impact on the geometry of the arterial lumen can
affect the wall stress and ultimately result in variable pattern of
aneurysm growth. A prospective longitudinal is therefore required
to assess the changes in thrombus volume, resultant change in
lumen curvature, and pattern of aneurysm growth/expansion,
before we can say that tortuosity of lumen centerline is the key
determinant of increasing the aneurysm wall stress.
Another important area worth exploring is the material behav-
ior of intraluminal thrombus. It is most likely a non-homogeneous
material with a complex property. A large ex vivo experiment is
needed for future study in this area to improve our understanding
of aneurysm material properties and failure strength. This can help
in creating more realistic computational models, which could be
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Regarding “Risk-adjusted 30-day outcomes of carotid
stenting and endarterectomy: Results from the SVS
Vascular Registry”
We have read the study by Sidawy et al1 about 30-day out-
comes of carotid artery stenting (CAS) compared with endarterec-
tomy (CEA) with great interest. Unfortunately, we are forced to
conclude that major flaws in the study prevent drawing meaningful
conclusions from this observational cohort study. Although cohort
studies can sometimes be powerful tools in assessing treatment
effectiveness,2 the authors’ study fails to meet minimal standards
for such studies; most importantly, (1) complete and unbiased
follow-up of study end points, and (2) rigorous control for con-
founders.
The validity of the conclusions drawn from a study such as
theirs, with only 44% follow-up, is extremely limited. Those lost to
follow-up are likely to be less adherent to concomitant drug
therapy and are often more likely to have had complications; or in
contrast, sometimes those who are doing extremely well may waive
follow-up visits.3-5 In general, 80% follow-up in longitudinal stud-
ies is considered a minimum, and 90% follow-up is generally
feasible in short follow-up studies like that of Sidawy et al.1 This
study’s poor follow-up is made worse by the different follow-up
rates between groups, by the reliance on self-report, and by
the presence of systematic differences between CEA and CAS
follow-up, because Centers for Medicare and Medicaid Servicesrules require in-hospital results for CAS for recertification,
whereas there is no such mandate for CEA.
Furthermore, controlling for all potential confounders is al-
ways important in cohort studies, but particularly in those in which
the choice of intervention is heavily influenced by patient factors
(ie, “selection”).2 Those who are more frail or who have higher
surgical risk are generally much more likely to have a minimally
invasive procedure (CAS) instead of a surgery (CEA), and biases
due to such patient and provider selection are notoriously difficult
to adjust for in cohort studies, usually requiring special methods
such as instrumental variable analyses.2
The results of Sidawy et al are in conflict with several random-
ized controlled trials comparing these two interventions and re-
porting equivalence of the two interventions,6-9 even in the long-
term.6 Therefore, we suggest that the short-term differences found
in this observational cohort study with poor follow-up and likely
inadequate control for confounding do not provide useful evi-
dence on this important clinical topic.
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Reply
The authors appreciate the comments from Drs Meier and
Hayward indicating potential flaws in our article, the first being
lack of complete and unbiased follow-up and the second being
inability for rigorous control for confounders. These weaknesses
were already identified as issues inherent to a study based on
